Clinical Evaluation of a Daily Wear Silicone Hydrogel Lens

NCT ID: NCT04207749

Last Updated: 2022-02-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

249 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-22

Study Completion Date

2020-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical study is to assess the safety and performance of an investigational soft contact lens compared to a commercially available soft contact lens when worn in a daily wear modality with frequent replacement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will attend 4 office visits: Screening/Baseline/Dispense; Week 1 Follow-up; Month 1 Follow-up; and Month 3 Follow-up/Exit. The total expected duration of participation for each subject is approximately 3 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractive Errors Myopia Hyperopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LID015385

LID015385 contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.

Group Type EXPERIMENTAL

LID015385 contact lenses

Intervention Type DEVICE

Investigational soft contact lenses

CLEAR CARE

Intervention Type DEVICE

Hydrogen peroxide-based cleaning and disinfecting solution

Biofinity

Comfilcon A contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.

Group Type ACTIVE_COMPARATOR

Comfilcon A contact lenses

Intervention Type DEVICE

Commercially available soft contact lenses

CLEAR CARE

Intervention Type DEVICE

Hydrogen peroxide-based cleaning and disinfecting solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LID015385 contact lenses

Investigational soft contact lenses

Intervention Type DEVICE

Comfilcon A contact lenses

Commercially available soft contact lenses

Intervention Type DEVICE

CLEAR CARE

Hydrogen peroxide-based cleaning and disinfecting solution

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BIOFINITY®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Understand and sign an IRB/IEC approved Informed Consent form.
* Willing and able to attend all scheduled study visits and wear the assigned study lenses as required per protocol.
* Successful wear of frequent replacement, spherical, daily wear soft contact lenses for distance correction in both eyes during the past 3 months for a minimum of 5 days per week and 8 hours per day.
* Manifest cylinder ≤ 0.75 diopter (D) in each eye.
* Best spectacle corrected visual acuity 20/20 or better in each eye.

Exclusion Criteria

* Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment.
* Monovision contact lens wear.
* Any habitual wear of Biofinity lenses.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sr. Clinical Trial Lead, CDMA Vision Care

Role: STUDY_DIRECTOR

Alcon Research, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alcon Investigator 8103

Glendale, Arizona, United States

Site Status

Alcon Investigator 8101

Brentwood, California, United States

Site Status

Alcon Investigator 8102

Irvine, California, United States

Site Status

Alcon Investigator 8135

Los Angeles, California, United States

Site Status

Alcon Investigator 8108

Novato, California, United States

Site Status

Alcon Investigator 8062

Oakland, California, United States

Site Status

Alcon Investigator 8109

San Francisco, California, United States

Site Status

Alcon Investigator 6565

Maitland, Florida, United States

Site Status

Alcon Investigator 6355

Orlando, Florida, United States

Site Status

Alcon Investigator 8115

Norcross, Georgia, United States

Site Status

Alcon Investigator 6567

Pittsburg, Kansas, United States

Site Status

Alcon Investigator 8063

Brighton, Massachusetts, United States

Site Status

Alcon Investigator 8100

New York, New York, United States

Site Status

Alcon Investigator 4817

Cleveland, Ohio, United States

Site Status

Alcon Investigator 6313

Powell, Ohio, United States

Site Status

Alcon Investigator 6401

Warwick, Rhode Island, United States

Site Status

Alcon Investigator 6353

Memphis, Tennessee, United States

Site Status

Alcon Investigator 8114

Plano, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLL949-C018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.